USPTO 2015–2025 USPTO PatentsView US Corporation

Mylan Inc.

USPTO PatentsView assignee record - 41 granted patents across 36 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61J (Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices ).

RSS updates for this company

The verdict

According to USPTO PatentsView, Mylan ranks #7,891 of 49,997 tracked US assignees by granted-patent volume, with 41 patents across 36 technology areas.

#7,891
of 49,997 US assignees by volume
Top 19%
by Innovation Score (47.2/100)
20.1
avg claims per patent
-72%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7891 · US Corporation #7,891 · 41 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-SMALL 41 grants
  • UPPER-Q #7,891/49,997
  • PHOTO-FINISH Medtronic CV…
  • CPC-FOCUS A61J · 36 areas
  • INNOV-PAR 47.2/100
  • CLAIMS-DENSE 20.1 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -72% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Medtronic CV Luxembourg S.A.R.L. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Mylan

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Mylan's Innovation Score is 47.2/100 (top 19% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Mylan's grants concentrate

Mylan Inc. is a focused PatentsView assignee: 36 CPC subclasses with 34.1% of grants classified under A61J (Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices ). Peak complete grant year is 2017 (12 grants) versus a trough of 1 in 2022. By volume, Mylan sits between Medtronic CV Luxembourg S.A.R.L. and National University Corporation Ehime University.

Mylan's three-year grant acceleration

Mylan Inc. shows 2 grants in 2022–2024 against only 13 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Mylan's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Mylan holds 41 patents at rank #7,891, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Mylan

By rank, the assignees closest to #7,891 in granted patent volume.

Leaders in A61J (Containers Specially Adapted FOR Medical OR Pharmaceutica…)

Other assignees with the most granted patents in Mylan's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Mylan, neither rank-band nor same-CPC leaders (those blocks stay above).

Mylan's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 19% higher than 81% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

051015 201520162017201820192020202120222024 1
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Mylan Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 5 12.2%
2016 6 14.6%
2017 12 29.3%
2018 3 7.3%
2019 6 14.6%
2020 5 12.2%
2021 2 4.9%
2022 1 2.4%
2024 1 2.4%

Which technologies does Mylan Inc. patent most?

Top 15 of 36 technology areas

Where it ranks

Overall rank by patents

#7,891

of 49,997 tracked assignees

Innovation Score

47.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Mylan Inc.'s patent record in context - here's where to go next.

  • Mylan Inc.'s lead technology class is A61J (Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices ), 34.1% of its portfolio - see every assignee active in that class. Explore A61J
  • Ranked #7,891 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Mylan Inc. against Medtronic CV Luxembourg S.A.R.L., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 47.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.